Table 1.
Baseline characteristics of immunocompromised patients who received early combined therapy (ECT) against COVID-19. Data are presented as number (n.) and percentage (%) or median and interquartile range (IQR).
| Baseline characteristics | |
|---|---|
| Patients, n. | 48 |
| Age, median (IQR) | 58 (45–73) |
| Male gender, n. (%) | 27 (56.2) |
| BMI, median (IQR) | 26.6 (22.3–29.3) |
| Charlson Comorbidity Index (CCI), median (IQR) | 5 (3–8) |
| Underlying comorbidities | |
| Hematological malignancy, n. (%) | 31 (64.6) |
| Non-Hodgkin lymphoma, n. (%) | 24 (50) |
| Receiving anti-CD20 monoclonal antibodies, n. (%) | 18 (37.5) |
| Chronic lymphocytic leukemia, n. (%) | 7 (14.6) |
| Hematopoietic stem cell transplant, n. (%) | 3 (6.2) |
| Solid transplant, n. (%) | 8 (16.7) |
| Kidney, n. (%) | 7 (14.6) |
| Liver, n. (%) | 1 (2.1) |
| Autoimmune disorders, n. (%) | 7 (14.6) |
| Requiring anti-CD20 monoclonal antibodies, n. (%) | 6 (12.5) |
| Hypertension, n. (%) | 21 (43.7) |
| Obesity, n. (%) | 8 (16.7) |
| Chronic obstructive pulmonary disease, n. (%) | 2 (4.2) |
| Cirrhosis, n. (%) | 1 (2.1) |
| Diabetes, n. (%) | 6 (12.5) |
| History of stroke or myocardial infarction, n. (%) | 7 (14.6) |
| Chronic kidney disease, n. (%) | 9 (18.7) |
| Solid cancer, n. (%) | 5 (10.4) |
| COVID-19 severity according to National Institute of Health (NIH) | |
| Asymptomatic, n. (%) | 4 (8.3) |
| Mild, n. (%) | 44 (91.7) |
| Vaccinal status | |
| Non vaccinated, n. (%) | 10 (20.8) |
| Two doses or less, n. (%) | 15 (31.2) |
| Three doses or more, n. (%) | 24 (50) |
| Cycle threshold (Ct) values | |
| RNA-dependent RNA polymerase (RdRP), median (IQR) | 22 (20–25) |
| Envelope (E) gene, median (IQR) | 20 (16–24) |
| Nucleocapsid (N) gene, median (IQR) | 20 (17–23) |
| Laboratory findings on day of ECT | |
| Positive SARS-CoV-2 anti-spike serology, n. (%) | 16 (33.3) |
| White blood cells count, 109 cells/L, median (IQR) | 4.42 (3.43–5.55) |
| Lymphocytes count, 109 cells/L, median (IQR) | 0.84 (0.67–1.17) |
| Interleukin-6, pg/mL, median (IQR) | 7 (5–15) |
| LDH, UI/L, median (IQR) | 225 (204–268) |
| PCR, mg/L, median (IQR) | 9 (6–17) |
| Days from positive nasopharyngeal swab to ECT, median (IQR) | 2 (1–3) |
| Days from onset of symptoms to ECT, median (IQR) | 3 (2–5) |